摘要
FMS样酪氨酸激酶受体3-内部串联重复（FLT3-ITD）突变作为急性髓细胞白血病（acutemyeloidleukemia，AML）的高危因素之一，与不良预后显著相关。索拉非尼是一种口服的小分子多重激酶抑制剂，近年来的研究发现其对多种癌症的疗效值得期待，包括FLT3-ITD突变阳性的AML。
Summary FLT3-ITD mutation is one of the poor-risk factors in acute myeloid leukemia （AML） ,and presents in 20% to 25% of AML patients. Recent researches reveal that FLT3 inhibitors could produce a promising antileukemia effect as target agents in FLT3-ITD mutation-positive cases. Sorafenib is the only available FTL3 inhibitor in China,and clinical studies have preliminarily proved its efficacy as well as safety. Better response could be anticipated when administered in coordination, but optimal dose and schedule has yet to be established.
出处
《临床血液学杂志》
CAS
2015年第2期267-269,共3页
Journal of Clinical Hematology
基金
江苏省科教兴卫工程--临床医学中心(No:ZX201102)
国家临床重点专科建设项目
卫生公益性行业科研专项经费项目(No:201202017)
国家高技术研究发展计划(863计划)课题(No:2012AA02A505)
